JGC
CSCI

J. Goldman & Co’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

J. Goldman & Co’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed -$59K – 377
2019
Q2 		$59K Sell
200
-3,540
-95% -$1.25M ﹤0.01% 255
2019
Q1 		$1.74M Sell
3,740
-6,235
-63% -$2.42M 0.1% 174
2018
Q4 		$2.93M Buy
+9,975
New +$2.38M 0.23% 122

Other funds holding CSCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return

J. Goldman & Co's CSCI Position: Q3 2019 in Review

J. Goldman & Co sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2019, closing a stake of 200 shares — an estimated $59K sold.

J. Goldman & Co first reported a position in CSCI in Q4 2018 and held it in 3 quarters. The position peaked at $2.93M in Q4 2018. 26 funds tracked by Wall St. Rank hold CSCI as of Q3 2019.

  • J. Goldman & Co reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • J. Goldman & Co sold 200 COSCIENS Biopharma Inc. Common Stock shares in Q3 2019, an estimated $59K.
  • J. Goldman & Co first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2018 and held it in 3 quarters.
  • J. Goldman & Co's COSCIENS Biopharma Inc. Common Stock position peaked at $2.93M in Q4 2018.
  • 26 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2019.

Based on J. Goldman & Co's 13F filing for Q3 2019, filed 14 Nov 2019.